Old Web
English
Sign In
Acemap
>
authorDetail
>
Richard Schaub
Richard Schaub
Incyte
Medicine
Pharmacodynamics
Pathology
Oncology
Internal medicine
6
Papers
239
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Pharmacodynamic assessment of INCB024360, an inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), in advanced cancer patients.
2017
Journal of Clinical Oncology
Robert Newton
Peggy Scherle
Kevin Bowman
Xiangdong Liu
Gregory L. Beatty
Peter J. O’Dwyer
Thomas F. Gajewski
J. D. Bowman
Richard Schaub
Lance Leopold
Show All
Source
Cite
Save
Citations (23)
Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies.
2017
Journal of Clinical Oncology
Gregory L. Beatty
Peter J. O’Dwyer
Jason Clark
Jack G. Shi
Robert Newton
Richard Schaub
Janet Maleski
Lance Leopold
Thomas F. Gajewski
Show All
Source
Cite
Save
Citations (33)
Interim analysis of a phase I study of INCB040093, a PI3Kδ inhibitor, alone or in combination with INCB039110, a selective JAK1 inhibitor, in patients (pts) with relapsed or refractory (r/r) B-cell malignancies.
2015
Journal of Clinical Oncology
Tycel Phillips
Andres Forero-Torres
Taimur Sher
Catherine Diefenbach
Moshe Talpaz
Peggy Scherle
Richard Schaub
Li Zhou
Jennifer Pulini
Lance Leopold
Matthew A. Spear
Paul M. Barr
Show All
Source
Cite
Save
Citations (8)
1